Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of MDM2 inhibitor KRT-232 in
treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back
(recurrent). MDM2 inhibitor KRT-232 may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth.